These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 29580033)
1. Evaluation the Anti-Cancer Effect of PEGylated Nano-Niosomal Gingerol, on Breast Cancer Cell lines (T47D), In-Vitro. Behroozeh A; Mazloumi Tabrizi M; Kazemi SM; Choupani E; Kabiri N; Ilbeigi D; Heidari Nasab A; Akbarzadeh Khiyavi A; Seif Kurdi A Asian Pac J Cancer Prev; 2018 Mar; 19(3):645-648. PubMed ID: 29580033 [TBL] [Abstract][Full Text] [Related]
2. Anti-cancer activity of pegylated liposomal trans-anethole on breast cancer cell lines MCF-7 and T47D. Shahbazian S; Akbarzadeh A; Torabi S; Omidi M Biotechnol Lett; 2015 Jul; 37(7):1355-9. PubMed ID: 25792512 [TBL] [Abstract][Full Text] [Related]
3. Preparation, Characterization and Cytotoxicity of Silibinin- Containing Nanoniosomes in T47D Human Breast Carcinoma Cells. Amiri B; Ebrahimi-Far M; Saffari Z; Akbarzadeh A; Soleimani E; Chiani M Asian Pac J Cancer Prev; 2016; 17(8):3835-8. PubMed ID: 27644625 [TBL] [Abstract][Full Text] [Related]
4. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation. Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340 [TBL] [Abstract][Full Text] [Related]
5. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study. Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, Characterization, and In-Vitro Evaluation of Silibinin-loaded PEGylated Niosomal Nanoparticles: Potential Anti-Cancer Effects on SW480 Colon Cancer Cells. Alali U; Mohammed Kadhim Al-Tu'ma M; Fadhil Jawad A; Talib Ahmed S; Addai Ali H; Abdulzehra S; Jawad Al-Tu'ma F Asian Pac J Cancer Prev; 2024 Jul; 25(7):2539-2550. PubMed ID: 39068589 [TBL] [Abstract][Full Text] [Related]
8. Encapsulation of gingerol into nanoliposomes: Evaluation of in vitro anti-inflammatory and anti-cancer activity. Alshaikh F; Al-Samydai A; Issa R; Alshaer W; Alqaraleh M; Al-Halaseh LK; Alsanabrah A; Ghanim BY; Al Azzam KM; Qinna NA Biomed Chromatogr; 2024 Aug; 38(8):e5899. PubMed ID: 38797863 [TBL] [Abstract][Full Text] [Related]
9. Bioresponsive gingerol-loaded alginate-coated niosomal nanoparticles for targeting intracellular bacteria and cancer cells. Pashizeh F; Mansouri A; Bazzazan S; Abdihaji M; Khaleghian M; Bazzazan S; Rezei N; Eskandari A; Mashayekhi F; Heydari M; Tavakkoli Yaraki M Int J Biol Macromol; 2024 Feb; 258(Pt 2):128957. PubMed ID: 38154726 [TBL] [Abstract][Full Text] [Related]
10. Growth Factor-Loaded Nano-niosomal Gel Formulation and Characterization. Moghassemi S; Hadjizadeh A; Hakamivala A; Omidfar K AAPS PharmSciTech; 2017 Jan; 18(1):34-41. PubMed ID: 27502406 [TBL] [Abstract][Full Text] [Related]
11. Design and optimization various formulations of PEGylated niosomal nanoparticles loaded with phytochemical agents: potential anti-cancer effects against human lung cancer cells. Shahbazi R; Jafari-Gharabaghlou D; Mirjafary Z; Saeidian H; Zarghami N Pharmacol Rep; 2023 Apr; 75(2):442-455. PubMed ID: 36859742 [TBL] [Abstract][Full Text] [Related]
13. A novel formulation of [6]-gingerol: Proliposomes with enhanced oral bioavailability and antitumor effect. Wang Q; Wei Q; Yang Q; Cao X; Li Q; Shi F; Tong SS; Feng C; Yu Q; Yu J; Xu X Int J Pharm; 2018 Jan; 535(1-2):308-315. PubMed ID: 29126908 [TBL] [Abstract][Full Text] [Related]
14. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation. Shaji J; Menon I Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699 [TBL] [Abstract][Full Text] [Related]
15. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185 [TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir. Akhter S; Kushwaha S; Warsi MH; Anwar M; Ahmad MZ; Ahmad I; Talegaonkar S; Khan ZI; Khar RK; Ahmad FJ Drug Dev Ind Pharm; 2012 Jan; 38(1):84-92. PubMed ID: 21726136 [TBL] [Abstract][Full Text] [Related]
17. Efficient Delivery of Gold Nanoparticles and miRNA-33a Via Cationic PEGylated Niosomal Formulation to MCF-7 Breast Cancer Cells. Ahmadi SM; Seyedabadi M; Ebrahimnejad P; Abasi M; Nokhodchi A AAPS PharmSciTech; 2024 Sep; 25(7):213. PubMed ID: 39266895 [TBL] [Abstract][Full Text] [Related]
18. Co-delivery of artemisinin and metformin via PEGylated niosomal nanoparticles: potential anti-cancer effect in treatment of lung cancer cells. Abdulkareem SJ; Jafari-Gharabaghlou D; Farhoudi-Sefidan-Jadid M; Salmani-Javan E; Toroghi F; Zarghami N Daru; 2024 Jun; 32(1):133-144. PubMed ID: 38168007 [TBL] [Abstract][Full Text] [Related]
19. Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin. Pawar S; Vavia P J Drug Target; 2016; 24(1):68-79. PubMed ID: 26152812 [TBL] [Abstract][Full Text] [Related]
20. pH responsive controlled release of anti-cancer hydrophobic drugs from sodium alginate and hydroxyapatite bi-coated iron oxide nanoparticles. Manatunga DC; de Silva RM; de Silva KMN; de Silva N; Bhandari S; Yap YK; Costha NP Eur J Pharm Biopharm; 2017 Aug; 117():29-38. PubMed ID: 28330763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]